报价延迟最少15分钟:2025/09/17 05:54 EDT
盘前时段
|
||||
|
1.79 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.78
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-43.87/-3.66
|
|
企业价值
16.65M
|
| 资产负债 |
|
每股账面净值
9.69
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
30.78M
|
|
每股收益
6.73
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/17 05:54 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, ofwhich the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software. |
